

Pharmacy Utilization Meeting

March 15, 2024

Attendees

Linda Coyle (IMS) – absent

Jennifer Stevens (IMS)

David Angelaszek (IMS)

Emily Carver (IMS)

Kevin Ward (Georgia) – absent

Randi Rycroft (Idaho) – absent

Serban Negoita (NCI)

Peggy Adamo (NCI) – absent

Marina Matatova (NCI)

Jennifer Hafterson (Seattle)

Tiffany Janes (Seattle)

Kaitlin Akif (NCI)

Kathy Cronin (NCI)

Nadia Howlader (NCI) – absent

Steve Scoppa (IMS) – absent

Gretchen Flynn (IMS)

- David presented on the interpretation of 00 vs blank in the augmented fields.
 - A modality with a blank value for the RX Summ augmented field means the patient did not have any pharmacy fills for an agent that is a typical first course treatment for that cancer.
 - A value of 00 for the RX Summ augmented field means the patient did have pharmacy fills for an agent that is a typical first course treatment for that cancer but the timing of the treatment with respect to the date of diagnosis did not allow for a value of 01 or 88 to be set according to the business rules developed by the workgroup. In these situations, the corresponding CTC summary value is copied to the augmented field which is how a value of 00 is populated.
- Serban presented his findings on the proportion of linked cases by cancer type using EOD ID for 17 registries and DX dates in 2010-2021.
- In 2020, max of 9.1% of cases for cancer types = soft tissue, breast, corpus carcinoma, ovary, prostate, brain, lymphoma, plasma cell myeloma/disorders hemeretic had linked pharmacy cases.
- The proportion dropped to 4% in 2010.
- Serban recommended 2010 be the cutoff year for analyses of pharmacy augmentation.